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Background and Aims: Type 2 diabetes is a progressive 
disease and its treatment eventually requires multiple-agent 
therapy, including insulin. PROactive was a cardiovascular 
outcome study, which examined the effects of pioglitazone 
on patients whose type 2 diabetes had been diagnosed on 
average 9.5 years before study entry. Little data exists on 
the benefits of using triple oral therapy (metformin 
+sulfonylurea+thiazolidinedione) in those patients failing 
dual oral treatment. This subanalysis evaluates the longterm 
glycaemic effects of pioglitazone add-on therapy in 
patients with type 2 diabetes and macrovascular disease 
who entered on metformin plus sulfonylurea. 
Materials and Methods: PROactive randomised patients 
to either pioglitazone or placebo, in addition to other 
glucose-lowering and cardiovascular medication, which 
was adjusted as necessary to treat to IDF target. Pioglitazone 
doses were force-titrated from 15 mg to 45 mg. Mean 
follow-up was 34.5 months. In total, 1314 patients entered 
the study on metformin plus sulfonylurea. Within this 
cohort, mean baseline HbA1c values were similar between 
groups (pioglitazone: 8.16%; placebo: 8.14%). 
Results: Significantly greater reductions in HbA1c were 
seen with pioglitazone (j0.9%) compared with placebo 
(j0.4%, P<0.0001). The significant improvement in HbA1c 
with pioglitazone versus placebo was shown with the 
following changes in associated glucose-lowering medication: 
more pioglitazone patients had either metformin or 
sulfonylurea dropped from their regimen (16%) and fewer 
had insulin added to their regimen (16%) than did placebo 
patients (8% and 31%, respectively). The metformin dose 
increased by 19 mg with pioglitazone versus 228 mg with 
placebo (P<0.0001). Sulfonylurea doses decreased or were 
unchanged in the pioglitazone group (j1.4 mg for glibenclamide 
versus j0.2 mg for placebo, P=0.013;j33 mg 
for gliclazide versus j23 mg for placebo, P=0.270; 0 mg 
for glimepiride versus+0.6 mg for placebo, P=0.009). 
Oedema occurred in 29% of patients in the pioglitazone 
group versus 17% in the placebo group (P<0.0001) and 
hypoglycaemia occurred in 27% in the pioglitazone group 
versus 20% in the placebo group (P=0.0013). There was a 
weight increase of 4.1 kg in the pioglitazone group and a 
decrease of 0.7 kg in the placebo group (P<0.0001). 
 
Conclusion: Little data exist on the benefits of triple oral 
therapy in patients with type 2 diabetes. Adding pioglitazone 
to a dual oral therapy regimen (metformin+sulfonylurea), 
thus resulting in a triple oral regimen, resulted in a sustained 
improvement in glycaemic control and a reduced need for 
insulin, with a good overall safety profile. 
  
